Company: SWKH
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001628280-25-025955
Chunk: 78

Company: SWK Holdings Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 78
---
 of SharesExercise Price per Share ($)GAAP BalanceYear-to-Date4Web, Inc. TBD $— $— $— ImpediMed12,491,870 0.05169 (134)Aziyo Biologics, Inc. Tranche 1157,895 6.65196 (157)Aziyo Biologics, Inc. Tranche 230,075 6.6537 (30)Biotricity, Inc. Tranche 157,356 37.562 — Biotricity, Inc. Tranche 2600,000 0.50196 33 CDMO Manufacturer211,442 1.42— — DxTerity Diagnostics, Inc.2,019,231 — — — Epica International, Inc. TBD — — — Eton Pharmaceuticals, Inc. Tranche 151,239 5.86 403 (21)Eton Pharmaceuticals, Inc. Tranche 218,141 6.62 141 (7)Eton Pharmaceuticals, Inc. Tranche 3289,736 5.32 2,922 (86)Shield Warrant8,910,540 0.14 179 (22)MedMinder, System, Inc. Tranche 157,859 10.37 — — MedMinder Systems, Inc. Tranche 214,465 10.37 — — Neolight, LLC52,524 7.62 — — MolecuLight, Inc. TBD — — — Revenue  RecognizedAssetsYear-to-DateTotal finance receivables, gross$231,861 $8,688 Total finance receivables and related interest receivable held for sale33,990 2,024 Total marketable investments455 — Total fair value of warrant assets4,245 — Total$270,551 $10,712 

 (1)US royalty was paid off continues to receive insignificant royalties on international sales.(2)Investment considered partially impaired.(3)Investment on non-accrual.(4)Investment was paid off and SWK continues to receive royalties on actual sales.(5)Flowonix Medical assets were sold to a medical device company in a prior period. In exchange for releasing its